Overview

SelectX Pharmaceuticals, Inc. is rapidly establishing itself as a leader in applied biosynthesis, combinatorial genetics, and directed evolution for the exploitation of molecular diversity and complexity in small molecules for drug discovery. The Company focuses its drug discovery and development on antimicrobial and anticancer therapeutics. SelectX has developed four complementary platform technologies: (1) Directed Discovery™ – an integrated molecular genetics/bioinformatics/biochemical platform for lead compound discovery; (2) ComGene™ – combinatorial genetics-based lead compound molecular diversity engine; and (3) DART™ – discovery and characterization of antibiotic resistance prior to clinical emergence. With the full deployment of these platforms, the Company’s proprietary preclinical pipeline is growing rapidly.  In stark contrast to most natural product-like discovery approaches, a unique advantage to SelectX is that product scale–up has been built into the core of the Company's discovery platform.

Science & Technology Strategy

From its inception, SelectX's technical strategy has focused on exploiting applied biosynthesis, combinatorial genetics, and directed discovery of novel, high-potential lead compounds.

The Company's technical strategy is the application of its three revolutionary platform technologies to efficiently discover, screen, and characterize potentially valuable small molecules.  This increased efficiency results in up to a 70% reduction in both the time and cost of drug discovery.  In addition to the inherent value of these technologies, is the value of their product - high quality lead compound libraries with unmatched molecular diversity, the key to both the medicinal potential and subsequent value of any lead compound library.

SelectX's proprietary technology platforms form the foundation for the Company's in-house drug discovery program which is focused on novel antiinfective, anticancer, and cardiovascular lead compounds. As part of this program, the Company is also pursuing the accurate prediction of antibiotic resistance prior to clinical emergence and subsequent strategies for overcoming the rapidly mounting problems of drug resistance.

Directed Discovery™: A platform for exploiting molecular diversity and complexity for generating focused, chemotype-selective small molecule libraries and lead compounds.

ComGene™:  A Combinatorial Genetics based small molecule molecular diversity engine.

DART™:  Drug and Antibiotic Resistance Technology, a platform for the accurate prediction and characterization of antibiotic resistance prior to clinical emergence.

Business Strategy

SelectX's business strategy is to rapidly develop an innovative, high potential preclinical pipeline using its innovative platform technologies, Directed Discovery™, ComGene™, and DART™.  This includes forming strategic alliances and collaborations with leading pharmaceutical and biotechnology companies.  The value of the Company's technologies resides, in part, in the capability of these technologies to significantly reduce both the time and cost of drug development; provide high-potential lead compound libraries and drug candidates; and are broadly applicable for the discovery of a wide range of therapeutics.